Dermatology NewsFDA: Safety signal emerged with higher dose of tofacitinib in RA studyFebruary 26, 2019Psoriatic Arthritis
Dermatology NewsIxekizumab psoriasis outcomes, sliced and dicedFebruary 23, 2019PsoriasisPsoriatic Arthritis
Dermatology NewsAAD, NPF release two joint guidelines on treatment, management of psoriasisFebruary 21, 2019PsoriasisPsoriatic Arthritis
Dermatology NewsBiologics curb coronary artery plaques in severe psoriasisFebruary 10, 2019PsoriasisPsoriatic Arthritis
Dermatology NewsDifferent disease features found with family history of psoriasis versus PsAFebruary 7, 2019Psoriatic ArthritisPsoriasis
Dermatology NewsGuselkumab tops secukinumab over 48 weeks for plaque psoriasisJanuary 29, 2019PsoriasisPsoriatic Arthritis
Dermatology NewsComorbidities may cut effectiveness of psoriasis biologicsJanuary 25, 2019PsoriasisPsoriatic Arthritis
Dermatology NewsBrodalumab raced past ustekinumab to PASI 100January 13, 2019PsoriasisPsoriatic Arthritis
Dermatology NewsLongterm maintenance of PASI 75 responses observed with tildrakizumabJanuary 3, 2019PsoriasisPsoriatic Arthritis
Dermatology NewsCONDOR trial: Most psoriasis patients can be downshifted to reduced-dose biologicsJanuary 3, 2019PsoriasisPsoriatic Arthritis
Dermatology NewsBack pain criteria perform well in patients with active axial psoriatic arthritisDecember 28, 2018Psoriatic Arthritis
Dermatology NewsPositive results reported for ixekizumab versus adalimumab in PsADecember 19, 2018Psoriatic Arthritis
